Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2025
0mins
Should l Buy VRTX?
Source: Benzinga
U.S. Stock Market Overview: U.S. stock futures are down, with the Dow futures dropping over 200 points. Several companies, including Ichor Holdings and Palantir Technologies, reported disappointing earnings or guidance, leading to significant declines in their stock prices during pre-market trading.
Notable Stock Movements: Ichor Holdings shares fell 14.8% after missing earnings estimates, while other companies like Hyperscale Data and Immutep also experienced sharp declines following their recent performance updates.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VRTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VRTX
Wall Street analysts forecast VRTX stock price to rise
22 Analyst Rating
17 Buy
5 Hold
0 Sell
Strong Buy
Current: 474.270
Low
414.00
Averages
515.88
High
604.00
Current: 474.270
Low
414.00
Averages
515.88
High
604.00
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Faces Criticism Amid Innovation Challenges
- Regulatory Standards Controversy: Congressman Jake Auchincloss criticized FDA Commissioner Marty Makary for replacing standards of safety and efficacy with fear and favoritism, undermining patient confidence in new therapies and impacting the market launch of innovative drugs.
- Staffing Losses: The FDA has experienced significant staff reductions in its Center for Drug Evaluation and Research, with oncology review staff dropping from about 100 to below 60, which may lead to approval delays and incomplete response letters.
- Decline in Accelerated Approvals: In 2024, the FDA approved 20 drugs through the accelerated approval process, down from 9 the previous year, indicating a direct impact on drug approval efficiency due to the loss of experienced reviewers.
- New Therapy Approval Pathways: The FDA proposed a new system for approving personalized drugs aimed at rare diseases, intending to provide more flexible approval pathways, but this change has sparked widespread controversy, affecting the agency's core mission.
See More
CRISPR Therapeutics: Potential and Challenges in Gene Editing
- Therapeutic Progress: CRISPR's gene-editing therapy Casgevy was approved in 2023 for treating sickle cell disease and transfusion-dependent beta thalassemia, showcasing its revolutionary potential in healthcare.
- High Treatment Costs: Despite Casgevy's staggering price of $2.2 million, healthcare experts justify this cost due to its one-time treatment nature, which could save patients time and money in the long run.
- Financial Challenges: CRISPR reported a net loss of $581.6 million in 2025, an increase from the $366.3 million loss in 2024, highlighting the significant expenditure pressures the company faces as it rolls out Casgevy.
- Strong Cash Position: As of the end of last year, CRISPR had approximately $2 billion in cash and marketable securities, indicating that despite its losses, the company is not at immediate risk of running out of funds, maintaining long-term growth potential.
See More
CRISPR Therapeutics Faces Significant Challenges Amid Slow Rollout
- Escalating Financial Losses: CRISPR reported a net loss exceeding $580 million in 2025, a significant increase from the $366.3 million loss in 2024, highlighting the pressure from high expenditures during the rollout of the Casgevy treatment and ongoing financial struggles.
- Strong Cash Position: Despite the losses, CRISPR maintained approximately $2 billion in cash and marketable securities at the end of last year, which is sufficient to support its daily operations, having consumed $345 million in 2025, indicating that the company is not at immediate risk of running out of funds.
- Slow Product Rollout: Although Casgevy was approved in 2023 and patient initiations nearly tripled last year, its staggering price of $2.2 million and profit-sharing with Vertex Pharmaceuticals limit CRISPR's market earnings, adversely affecting its profitability.
- Uncertain Market Outlook: While CRISPR's gene-editing therapies hold long-term potential, the lack of current profitability and the risk assessment of its stock make it a cautious buy for investors, especially as it was not included in the list of top recommended stocks by analysts.
See More
Vertex Pharmaceuticals Officer Plans to Sell $19.74 Million in Common Stock via Form 144
Stock Sale Announcement: Kewalramani, an officer at Vertex Pharmaceuticals, plans to sell 40,000 shares of the company's common stock.
Market Value: The total market value of the shares being sold is approximately $19.74 million.
See More
Healthcare Sector Outlook: CVS and Vertex Prospects
- CVS Recovery: CVS Health's share price surged over 70% in 2025, and it is expected to maintain this growth momentum in 2026, despite plans to scale back its Medicare Advantage business to enhance long-term profitability, indicating a strategic shift towards sustainable growth.
- Strategic Focus: By exiting the Obamacare marketplace, CVS aims to concentrate on long-term profitability, which may not significantly impact short-term financial results but is likely to enhance its competitive position in the future.
- Vertex Drug Progress: Vertex Pharmaceuticals anticipates that its new drugs, Journavx and Casgevy, will generate at least $500 million in sales in 2026, which, while modest compared to its total revenue of $12 billion in 2025, highlights the potential for product line diversification.
- Clinical Advancements: Vertex plans to seek approval for its Type 1 diabetes drug, zimislecel, and will release phase 3 study data for treatments targeting IgA nephropathy and APOL-1 mediated kidney disease, further strengthening its market position and product portfolio.
See More
CVS Health and Vertex Pharmaceuticals Outlook
- CVS Health Strategic Shift: CVS Health plans to scale back its Medicare Advantage business in 2026, which may not significantly impact financial results in the short term but aims to enhance long-term profitability, thereby strengthening its leadership position in the healthcare sector.
- Stock Price Recovery: In 2025, CVS Health's share price soared over 70% due to improved financial results, laying a solid foundation for continued growth in 2026, reflecting the company's deep roots in the U.S. healthcare ecosystem and strong customer relationships.
- Vertex Pharmaceuticals New Product Progress: Vertex Pharmaceuticals expects its new products, Journavx and Casgevy, to generate at least $500 million in sales in 2026, which, while modest, will provide crucial support for the company's future revenue growth.
- Clinical and Regulatory Advances: Vertex plans to seek approval for its investigational medicine zimislecel for Type 1 diabetes in 2026 and release phase 3 study data for next-gen programs, further enhancing the diversity and competitiveness of its product lineup.
See More
FDA Faces Criticism Amid Innovation Challenges
- Regulatory Standards Controversy: Congressman Jake Auchincloss criticized FDA Commissioner Marty Makary for replacing standards of safety and efficacy with fear and favoritism, undermining patient confidence in new therapies and impacting the market launch of innovative drugs.
- Staffing Losses: The FDA has experienced significant staff reductions in its Center for Drug Evaluation and Research, with oncology review staff dropping from about 100 to below 60, which may lead to approval delays and incomplete response letters.
- Decline in Accelerated Approvals: In 2024, the FDA approved 20 drugs through the accelerated approval process, down from 9 the previous year, indicating a direct impact on drug approval efficiency due to the loss of experienced reviewers.
- New Therapy Approval Pathways: The FDA proposed a new system for approving personalized drugs aimed at rare diseases, intending to provide more flexible approval pathways, but this change has sparked widespread controversy, affecting the agency's core mission.
See More
CRISPR Therapeutics: Potential and Challenges in Gene Editing
- Therapeutic Progress: CRISPR's gene-editing therapy Casgevy was approved in 2023 for treating sickle cell disease and transfusion-dependent beta thalassemia, showcasing its revolutionary potential in healthcare.
- High Treatment Costs: Despite Casgevy's staggering price of $2.2 million, healthcare experts justify this cost due to its one-time treatment nature, which could save patients time and money in the long run.
- Financial Challenges: CRISPR reported a net loss of $581.6 million in 2025, an increase from the $366.3 million loss in 2024, highlighting the significant expenditure pressures the company faces as it rolls out Casgevy.
- Strong Cash Position: As of the end of last year, CRISPR had approximately $2 billion in cash and marketable securities, indicating that despite its losses, the company is not at immediate risk of running out of funds, maintaining long-term growth potential.
See More
CRISPR Therapeutics Faces Significant Challenges Amid Slow Rollout
- Escalating Financial Losses: CRISPR reported a net loss exceeding $580 million in 2025, a significant increase from the $366.3 million loss in 2024, highlighting the pressure from high expenditures during the rollout of the Casgevy treatment and ongoing financial struggles.
- Strong Cash Position: Despite the losses, CRISPR maintained approximately $2 billion in cash and marketable securities at the end of last year, which is sufficient to support its daily operations, having consumed $345 million in 2025, indicating that the company is not at immediate risk of running out of funds.
- Slow Product Rollout: Although Casgevy was approved in 2023 and patient initiations nearly tripled last year, its staggering price of $2.2 million and profit-sharing with Vertex Pharmaceuticals limit CRISPR's market earnings, adversely affecting its profitability.
- Uncertain Market Outlook: While CRISPR's gene-editing therapies hold long-term potential, the lack of current profitability and the risk assessment of its stock make it a cautious buy for investors, especially as it was not included in the list of top recommended stocks by analysts.
See More
Vertex Pharmaceuticals Officer Plans to Sell $19.74 Million in Common Stock via Form 144
Stock Sale Announcement: Kewalramani, an officer at Vertex Pharmaceuticals, plans to sell 40,000 shares of the company's common stock.
Market Value: The total market value of the shares being sold is approximately $19.74 million.
See More
Healthcare Sector Outlook: CVS and Vertex Prospects
- CVS Recovery: CVS Health's share price surged over 70% in 2025, and it is expected to maintain this growth momentum in 2026, despite plans to scale back its Medicare Advantage business to enhance long-term profitability, indicating a strategic shift towards sustainable growth.
- Strategic Focus: By exiting the Obamacare marketplace, CVS aims to concentrate on long-term profitability, which may not significantly impact short-term financial results but is likely to enhance its competitive position in the future.
- Vertex Drug Progress: Vertex Pharmaceuticals anticipates that its new drugs, Journavx and Casgevy, will generate at least $500 million in sales in 2026, which, while modest compared to its total revenue of $12 billion in 2025, highlights the potential for product line diversification.
- Clinical Advancements: Vertex plans to seek approval for its Type 1 diabetes drug, zimislecel, and will release phase 3 study data for treatments targeting IgA nephropathy and APOL-1 mediated kidney disease, further strengthening its market position and product portfolio.
See More
CVS Health and Vertex Pharmaceuticals Outlook
- CVS Health Strategic Shift: CVS Health plans to scale back its Medicare Advantage business in 2026, which may not significantly impact financial results in the short term but aims to enhance long-term profitability, thereby strengthening its leadership position in the healthcare sector.
- Stock Price Recovery: In 2025, CVS Health's share price soared over 70% due to improved financial results, laying a solid foundation for continued growth in 2026, reflecting the company's deep roots in the U.S. healthcare ecosystem and strong customer relationships.
- Vertex Pharmaceuticals New Product Progress: Vertex Pharmaceuticals expects its new products, Journavx and Casgevy, to generate at least $500 million in sales in 2026, which, while modest, will provide crucial support for the company's future revenue growth.
- Clinical and Regulatory Advances: Vertex plans to seek approval for its investigational medicine zimislecel for Type 1 diabetes in 2026 and release phase 3 study data for next-gen programs, further enhancing the diversity and competitiveness of its product lineup.
See More
